The prognostic and therapeutic impacts of CD30 expression have been investigated in Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), cutaneous T cell lymphoma (CTCL), and primary mediastinal B cell lymphoma (PMBCL) [7, 46]. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.